Liposomes comprising duramycin and anti-viral agents

Details Liposomes comprising duramycin and anti-viral agents Liposomes comprising duramycin and anti-viral agents

2011-07-12

2011-07-12

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

07976868

ABSTRACT:
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

REFERENCES:
patent: 4939098 (1990-07-01), Suzuki et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5627036 (1997-05-01), Reutelingersperger
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5834599 (1998-11-01), Chang et al.
patent: 5849706 (1998-12-01), Molina y Vedia et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6194430 (2001-02-01), Camden et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 7034113 (2006-04-01), Olstein et al.
patent: 7067109 (2006-06-01), Thorpe et al.
patent: 7247303 (2007-07-01), Thorpe et al.
patent: 7378386 (2008-05-01), Thorpe et al.
patent: 7384909 (2008-06-01), Thorpe et al.
patent: 7422738 (2008-09-01), Thorpe et al.
patent: 7455833 (2008-11-01), Thorpe et al.
patent: 7511124 (2009-03-01), Thorpe et al.
patent: 7550141 (2009-06-01), Thorpe et al.
patent: 7611704 (2009-11-01), Thorpe et al.
patent: 7678386 (2010-03-01), Thorpe
patent: 7790159 (2010-09-01), Thorpe et al.
patent: 7879801 (2011-02-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2003/0175207 (2003-09-01), Olstein et al.
patent: 2003/0228625 (2003-12-01), Toh et al.
patent: 2004/0131610 (2004-07-01), Thorpe et al.
patent: 2004/0131621 (2004-07-01), Thorpe et al.
patent: 2004/0131622 (2004-07-01), Thorpe et al.
patent: 2004/0147440 (2004-07-01), Thorpe et al.
patent: 2004/0161429 (2004-08-01), Thorpe et al.
patent: 2004/0175378 (2004-09-01), Thorpe et al.
patent: 2004/0208868 (2004-10-01), Thorpe et al.
patent: 2004/0213779 (2004-10-01), Thorpe et al.
patent: 2004/0219155 (2004-11-01), Thorpe et al.
patent: 2005/0002941 (2005-01-01), Thorpe et al.
patent: 2005/0031620 (2005-02-01), Thorpe et al.
patent: 2005/0129696 (2005-06-01), Thorpe et al.
patent: 2005/0136059 (2005-06-01), Thorpe et al.
patent: 2008/0066741 (2008-03-01), LeMahien et al.
patent: 08-092124 (1994-09-01), None
patent: 08092124 (1994-09-01), None
patent: WO 00/02584 (2000-01-01), None
patent: WO 00/02587 (2000-01-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 01/03735 (2001-01-01), None
patent: WO 01/68709 (2001-09-01), None
patent: WO 2004/006847 (2004-01-01), None
Machine translation of JP 08092124, Date et al, Sep. 1994, 3 pages.
Balasubramanian and Schroit, “Aminophospholipid Asymmetry: A Matter of Life and Death”,Annu. Rev. Physiol., 65:701-734, 2003.
Beck et al., “Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth and Metastasis of Orthotopic Pancreatic Tumors in Mice”,Int. J. Cancer, 118:2639-2643, 2006.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amnio Acid Substitutions”,Science, 147:1306-1310, 1990.
Güssow and Seemann, “Humanization of Monoclonal Antibodies”,Methods in Enzymology, 203:99-121, 1991.
Herbert et al., Eds., Dictionary of Immunology, 4th ed. London:Academic Press, 1995.
Huang et al., “A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice”,Cancer Res., 65(10):4408-4416, 2005.
Janeway et al., “The Interaction of the Antibody Molecule with Specific Antigen”,Immunobiology, 5th ed., 7 pages, 2001.
Lewis et al., “Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies”,Cancer Immunol. Immunother., 37:255-263, 1993.
Luster et al., “Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells,”JBC Papers in Press, www.jbc.org/cgi/doi/10.1074/jbc., M605252200:1-20, 2006.
Ran and Thorpe, “Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy”,Int. J. Radiation Oncology Biol. Phys., 54(5):1479-1484, 2002.
Ran et al., “Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice”,Clin. Cancer Res., 11:1551-1562, 2005.
Ran et al., “Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels”,Cancer Res.; 62:6132-6140, 2002.
Rudikoff, “Single Amino Acid Substitution Altering Antigen-Binding Specificity”,Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Schneider-Gadicke and Riethmüller, “Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours”,Eur. J. Cancer, 31A(7/8):1326-1330, 1995.
Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth”,Proc. Natl. Acad. Sci. USA, 88:8691-8695, 1991.
Strobel and Cannistra, “β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro”,Gynecologic Oncology, 73:362-367, 1999.
Thorpe et al., “Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors”,Proceeding of the American Association for Cancer Research, 36:488, Abstract #2910, Mar. 1995.
Contractual European Search Report for counterpart PCT Application, PCT/US03/21925, mailed Mar. 31, 2004.
European Search Report for Counterpart European Application No. 03764600.7, dated Dec. 27, 2004.
International Search Report for counterpart PCT Application, PCT/US03/21925, mailed Feb. 24, 2005.
Casset et al., “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design”,Biochem. Biophys. Res. Commun., 307(1):198-205, 2003.
Hortobagyi, “Developments in Chemotherapy of Breast Cancer”,Cancer, 88(S12):3073-3079, 2000.
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody”,J. Immunol., 169:3076-3084, 2002.
Paul, “Fv Structure and Diversity in Three Dimensions”,In Fundamental Immunology, Third Edition, 1993, pp. 292-295.
Aggarwal and Ranjan, “Preventing and Treating Hepatitis B Infection”,BMJ, 329:1080-1086, 2004.
Aoki et al., “A Novel Peptide Probe for Studying the Transbilayer Movement of Phosphatidylethanolamine”,J. Biochem., 116:291-297, 1994.
Borda et al., “Cell Tropism of Simian Immunodeficiency Virus in Culture Is Not Predictive of in Vivo Tropism or Pathogenesis”,Am. J. Pathol., 165(6):2111-2122, 2004.
Connor et al., “Differentiation-Dependent Expression of Phosphatidylserine in Mammalian Plasma Membranes: Quantitative Assessment of Outer-Leaflet Lipid by Prothrombinase Complex Formation”,Proc. Natl. Acad. Sci. USA, 86:3184-3188, 1989.
De Palma, “Looking Inside the Black Box/Biological Pathways and Drug Discovery”,New York Academy of Sciences, 1-3, 2006.
Emoto et al., “Exposure of Phosphatidylethanolamine on the Surface of Apoptotic Cells”,Exp. Cell Res., 232:430-434, 1997.
Ford et al., “The Intracellular Pharmacology of Antiretroviral Protease Inhibitors”,J. Antimibrobial Chemotherapy, 54:982-990, 2004.
Gaertner and Offord

Affiliated with

Also associated with

Rating

Liposomes comprising duramycin and anti-viral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomes comprising duramycin and anti-viral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomes comprising duramycin and anti-viral agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2670846